Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity

Core Insights - Rhythm Pharmaceuticals announced positive data from the Phase 3 TRANSCEND trial for setmelanotide in acquired hypothalamic obesity, showing an 18.8% placebo-adjusted difference in BMI reduction at 52 weeks [1][5] - The company aims to become the first to receive FDA approval for a therapy targeting acquired hypothalamic obesity, with a PDUFA goal date set for March 20, 2026 [2][3] Company Overview - Rhythm Pharmaceuticals is a biopharmaceutical company focused on rare neuroendocrine diseases, with its lead product, setmelanotide, designed to treat hyperphagia and severe obesity [6][8] - The company has received FDA approval for setmelanotide to reduce excess body weight in patients with specific genetic obesity syndromes [7][8] Clinical Trial Data - The TRANSCEND trial met its primary endpoint with a mean BMI reduction of 16.4% from baseline for patients on setmelanotide compared to a 2.4% increase for placebo [5] - Among patients aged 12 and older, the setmelanotide group showed a significant reduction in hunger scores, averaging a 2.5-point decrease compared to 1.3 points in the placebo group [5] Regulatory Pathways - Rhythm is in the process of submitting a supplemental New Drug Application (sNDA) to the FDA, with a final data package submission scheduled for March 2, 2026 [2][3] - The European Medicines Agency (EMA) is reviewing a Type II variation submission for setmelanotide, with an opinion expected in Q2 2026 [3] Market Potential - The estimated patient population for acquired hypothalamic obesity includes approximately 10,000 patients in the U.S., 10,000 in Europe, and between 5,000 to 8,000 in Japan [4]